AACR 2023 | Proposing the best MET inhibitor to improve anti-PD-1 efficacy in HCC

Hepatocellular carcinoma (HCC) remains among the most therapeutically intractable cancers, despite recent advances in immunotherapy options for this disease. The receptor tyrosine kinase MET and its ligand HGF are known drivers of HCC. Ricardo De Azevedo, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares insight into an evaluation of the synergistic activity of MET inhibition with blockade of the PD-1 immune checkpoint blockade to promote HCC tumor regression. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.